The spectrum of psychiatric manifestations in subacute sclerosing panencephalitis: a systematic review of published case reports and case series

Ravindra Kumar Garg
*Sujita Kumar Kar
Hardeep Singh Malhotra
Shweta Pandey
**Amita Jain
Imran Rizvi
Ravi Uniyal
Neeraj Kumar

Department of Neurology
King George’s Medical University
Lucknow, India: 226003

*Department of Psychiatry
King George’s Medical University
Lucknow, India: 226003

**Department of Microbiology
King George’s Medical University
Lucknow, India: 226003

Correspondence
Ravindra Kumar Garg
Department of Neurology
King George’s Medical University
Conflict of Interest All authors have no conflict of interest to report.
Background

Data related to psychiatric manifestations in SSPE is currently available only in form of isolated case reports. In this systematic review, we evaluated the spectrum of psychiatric manifestations and their impact on the course and outcome of SSPE.

Methods

Data were obtained from four databases (PubMed, Embase, Scopus, and Google Scholar), with the most recent search conducted on 27/03/2023. The PRISMA guidelines were followed, and the PROSPERO registration number for the protocol is CRD42023408227. SSPE was diagnosed using Dyken's criteria. Extracted data were recorded in an Excel spreadsheet. To evaluate the quality of the data, the Joanna Briggs Institute Critical Appraisal tool was employed.

Results

Our search resulted in 30 published reports of 32 patients. The mean age was 17.9 years. Schizophrenia, catatonia, and poorly characterized psychotic illnesses were the three most common psychiatric presentations (60%) in SSPE cases. Mania or depression was reported among 23% (7/32) cases. In 10% of cases, the initial clinical presentation of SSPE was considered functional/ hysterical. In approximately 81% (26/32) cases, the course of SSPE was rapidly progressive (either acute fulminant or
subacute). Treatment with antipsychotic drugs had poor or no response. Out of 17 patients who received antipsychotic drugs 6 patients noted severe extrapyramidal adverse effects, that further deteriorated the clinical condition of the patients.

Conclusion

Several patients with SSPE inadvertently end up in psychiatric care due to some psychiatric manifestation. Early psychiatric disorders in SSPE are often subtle and diagnosis of SSPE is easily missed.

Keywords:
Introduction

Subacute sclerosing panencephalitis (SSPE) is a relentlessly progressive brain disorder caused by the defective measles virus. SSPE is common in measles-endemic areas. SSPE usually presents with progressive cognitive deterioration and myoclonus. Children between 8 and 12 years of age are more frequently affected. SSPE is invariably fatal within 1–3 years from the onset. In an acute-fulminant variant of SSPE, the patient either dies or becomes akinetic mute within 6 months of disease onset.
Electroencephalography (EEG) reveals periodic discharges. Brain imaging reveals periventricular T2/ FLAIR white matter abnormalities. The advanced stage of SSPE is characterized by marked brain atrophy. A definitive diagnosis needs the demonstration of elevated measles antibody titers in the cerebrospinal fluid (CSF).\(^1,2\) Infrequently, pure psychiatric manifestations (like mania, psychosis, catatonia, and malingering) have also been reported in many SSPE patients. In this systematic review, we evaluated the spectrum of psychiatric manifestations of SSPE.

**Material and methods**

**Protocol registration**

We conducted a thorough analysis of published case reports and case series of SSPE patients, who either had psychiatric manifestations at the time of diagnosis or who later developed psychiatric manifestations. We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards for our systematic review. The protocol was made pre-registered in PROSPERO (CRD42023408227).\(^3\)

**Literature search**
A literature search was done in the databases of PubMed, Scopus, Embase, and Google Scholar. In Google Scholar database, first 50 pages were screened for relevant articles. No language restrictions were imposed, while databases are searched. Articles, other than in English language were translated into English with the help of “A Google translator”.

The following search items were used in our search strategy: (((((((((((((PSYCHIATRIC) OR (Neuropsychiatric)) OR (Schizophrenia)) OR (Mania)) OR (Psychosis)) OR (Depression)) OR (Catatonia)) OR (Attention deficits)) OR (Anxiety)) OR (Panic attacks)) OR (Sleep disorders)) OR (Nightmares)) OR (Parasomnias)) AND (SSPE). The date of the last search was 27/03/2023.

Exclusion criteria

The articles that were omitted, included editorials, comments on previously published cases, and review articles. Conference abstracts were also not taken into account.

Data extraction
The study was conducted in two stages. Titles and abstracts were assessed by two independent reviewers in the initial phase (RK and IR). The full texts of the chosen papers were then examined by an additional set of two reviewers to determine their eligibility following the inclusion criteria (RK and IR). A third author was brought in to settle any differences between the two authors (AJ).

Dyken's criteria were used to identify cases with a confirmed diagnosis of SSPE (Table-1). Studies were considered if they fulfilled the following criteria: (1) they were case reports or case series; (2) they described cases of psychiatric manifestations in a case of SSPE; (3) cohort studies were included only if, individual patient data were available; and (4) they comprehensively described the psychiatric manifestations in confirmed SSPE cases.

Quality of studies

The critical appraisal checklist for case reports and case series given by the Joanna Briggs Institute (JBI) was used to assess the quality of published case reports. The critical appraisal tool we used was an 8-item scale including the patient's demographic characteristics, clinical details, details of laboratory workup, the treatment administered, the follow-up clinical condition, adverse events, and the main takeaways from the case reports. Each of these criteria was used to evaluate every case. "Yes" or "No" was indicated for each point. Two independent
reviewers (SKK and RU) assessed the quality of the included cases, and any disagreements between them were resolved by mutual agreement, If still there was a dispute, it was resolved via discussion with a third reviewer (AJ).

**Data analysis**

Each patient's demographic information, history of measles infection or vaccination in infancy, length of illness, type of psychiatric manifestations, workup procedures, results of neuroimaging, and course and outcome were all noted. Four reviewers (RK, IR, HSM, and RU) completed all of them; in the event of a disagreement, assistance from a fifth reviewer was sought (AJ). To manage duplicate records, the web tool EndNote 20 (Clarivate Analytics) was employed. Two reviewers independently completed this process once more (SKK and AJ). Any problems were rectified with the assistance of another reviewer. A PRISMA flow chart was used to present the number of records that were retrieved and evaluated at each stage. PRISMA flow chart was prepared with the help of EndNote 20 (Clarivate Analytics). (Figure-1)

We used Microsoft Excel software, for data analysis. The necessary data was taken out and put together in an Excel document. The information we compiled included the first author, the nation of the report, the demographics of the patients, the status of childhood measles vaccination, childhood measles infection, length of illness, types of psychiatric manifestations, other clinical presentations, specifics of the reported diagnostic workup, neuroimaging, and the outcome. We focussed on the descriptive and...
Results

Our search resulted in 30 reports with information on 32 patients. (Table-2)6-35 We compiled our data as per PRISMA standards. (Supplementary file-1- PRISMA checklist) Figure-1 shows the PRISMA flowchart for our systematic review. Table-3 summarises the demographic, clinical, neuroimaging, and brain/retina biopsy information of SSPE cases with psychiatric manifestations.

A supplemental Word file contains the critical appraisal report of each included case, according to the Joanna Briggs Institute (JBI) checklist. (Supplementary file -2). In An 8-item scale, the majority of cases (26/32) complied with all the points. Only 6 cases faltered on the point “post-intervention clinical condition”.

The mean age of SSPE patients was 17.9 years (median 15 years and range 2-62 years). Men outnumbered the females (21: 11). Majority (94%) of SSPE patients with psychiatric presentations either did not have childhood measles vaccination, or a reliable vaccination history was not retrievable. In one-third of instances, childhood measles infection was reported by relatives. The
majority of reports (73.3%) on SSPE patients with psychiatric presentations were from Turkey and India. After the year 2005, all such reports were excluded from these two countries only. (Table-3)

Schizophrenia, catatonia, and poorly characterized psychotic illnesses were the three most common psychiatric presentations (60%) in SSPE cases. Affective disorders, mania, and depression were reported among 23% (7/32) cases. In 10% of cases, the initial clinical presentation of SSPE was considered functional/ hysterical. In approximately 81% (26/32) cases the course of SSPE was rapidly progressive (either acute fulminant or subacute). (Table-3)

Neuroimaging abnormalities were detected in 63% (10/16) of patients, periventricular T2/FLAIR MR hyperintensities were the most frequently noted abnormalities. Brain biopsy findings were noted in 3 patients. Focal demyelination with gliosis, inflammatory cell infiltration, and the presence of inclusion bodies in neurons and oligodendroglia were dominant histopathological findings. (Table-3)

Treatment with antipsychotic drugs had poor or no response. Out of 17 patients who received antipsychotic drugs 6 patients noted severe extrapyramidal adverse effects, that further deteriorated the clinical condition of the patients. (Table-3)

Discussion
In this systematic review, we noted that many patients with SSPE were mistakenly referred to psychiatric care because of their psychiatric presentations. These patients frequently received diagnoses of affective disorders, including mania and depression, as well as psychotic diseases like schizophrenia, catatonia, and poorly defined psychotic illnesses. Treatment with antipsychotic drugs often failed, and severe extrapyramidal adverse effects were common. In the early stages, many children were misdiagnosed as malingering or hysterical.

Our review found that schizophrenia was the most common psychiatric diagnosis for many cases of SSPE. Schizophrenia is a mental disorder characterized by delusions, hallucinations, disorganized thinking, and other symptoms. Anti-N-methyl-d-aspartate (NMDA) receptor encephalitis is another brain disorder that can cause similar symptoms. It is often misdiagnosed as a psychiatric disorder, just as SSPE was in our review. NMDA receptor encephalitis is characterized by psychotic and affective symptoms, catatonic signs, and mental decline. It is also often associated with seizures, abnormal movements, and a fluctuating course. Fulminant SSPE can mimic NMDA receptor encephalitis, making it difficult to distinguish between the two conditions.\(^{36-38}\)

The pathophysiology of underlying schizophrenia in SSPE is difficult to elucidate. The psychotic symptoms may result from the progressive destruction of brain tissue caused by chronic measles virus infection. One report indicated that individuals with persistent schizophrenia had significantly higher blood antimeasles antibody titers than those without a history of a psychiatric disorder.\(^{39}\) Many studies have shown that schizophrenia is associated with lower brain volume particularly of gray matter and
cortical thickness, increasing gray matter loss, and abnormal gyral patterns. Research has shown that there are structural changes in the brains of individuals with schizophrenia, and similar changes have been observed in the brains of individuals with SSPE. These changes include a reduction in brain volume, particularly in the frontal lobes, temporal lobes, and hippocampus, which are regions of the brain involved in cognitive and emotional processing. In patients with schizophrenia, neuropathological examinations and brain imaging studies suggest a variety of abnormalities in many brain regions, including the cerebral cortex, hippocampus, thalamus, and amygdala. Extrapyramidal reactions following treatment with antipsychotic medications are common and frequently lead to rapid deterioration. (Figure-2)

Catatonia is another frequent psychiatric manifestation in patients with SSPE. The pathogenesis of catatonia in SSPE is also not fully understood. Catatonia is believed to result from dysfunction of the frontostriatal network in the brain, which regulates motor and behavioral functions. The SSPE virus also targets the basal ganglia, which are a part of the frontostriatal circuitry. Damage to the basal ganglia can disrupt the normal functioning of this circuitry, leading to motor and behavioral abnormalities characteristic of catatonia. The measles virus targets the limbic system, which is responsible for emotional regulation. Damage to the limbic system may lead to dysfunction of the neural circuits involved in mood regulation, leading to depression. In addition to direct damage to brain tissue, alterations in neurotransmitter and immune system function are possible mechanisms involved in the pathogenesis of depression in SSPE.
Many times, particularly in the early stages of the disease, SSPE is inadvertently considered "malingering". "Malingering" refers to the intentional feigning or exaggeration of symptoms for external gain, such as to avoid school work, or to gain attention or sympathy.\textsuperscript{45,46}

In conclusion, many patients with SSPE inadvertently end up in psychiatric care due to their psychiatric symptoms. Early psychiatric manifestations in SSPE are often subtle and the diagnosis of SSPE is easily missed. We suggest that if there is no satisfactory response to antipsychotic drugs or if there are early extrapyramidal reactions leading to further deterioration, the possibility of SSPE should be considered.
Declarations

Financial or non-financial support for the review = None

Competing interests of review authors = None to declare
References


Table-1: Dyken’s diagnostic criteria of subacute sclerosing panencephalitis (SSPE)  
(Any three of 4 components )

<table>
<thead>
<tr>
<th>category</th>
<th>criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical</td>
<td>Progressive deterioration in mental function</td>
</tr>
<tr>
<td></td>
<td>periodic axial myoclonus</td>
</tr>
<tr>
<td>Electroencephalography</td>
<td>Periodic discharges</td>
</tr>
<tr>
<td>Cerebrospinal fluid</td>
<td>Serum globulin concentrations &gt; 20% of the total cerebrospinal fluid protein</td>
</tr>
<tr>
<td></td>
<td>Elevated cerebrospinal fluid measles antibody levels</td>
</tr>
<tr>
<td>Brain biopsy</td>
<td>Histopathology suggestive of panencephalitis</td>
</tr>
<tr>
<td></td>
<td>Inclusion bodies in neurons</td>
</tr>
<tr>
<td></td>
<td>Presence of measles virus or its genetic components in the brain</td>
</tr>
</tbody>
</table>
**Table-2: Epidemiological, clinical features, neuroimaging findings, histopathological features and outcome of patients of SSPE with psychiatric manifestations**

<table>
<thead>
<tr>
<th>Reference</th>
<th>Country</th>
<th>Age/sex</th>
<th>Measles vaccination</th>
<th>Childhood measles</th>
<th>Duration of illness before presentation</th>
<th>Psychiatric manifestation</th>
<th>Clinical features</th>
<th>Neuroimaging</th>
<th>Brain biopsy</th>
<th>Course of illness</th>
<th>Treatment and its response</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koehler and Jakumeit 1976</td>
<td>Germany</td>
<td>20/F Pregnant</td>
<td>NA</td>
<td>NA</td>
<td>2 weeks</td>
<td>Hysterical blindness</td>
<td>Vision loss Denial of vision loss She was cheerful despite vision loss Vision loss was interpreted as hysterical &quot;la belle indifference&quot; Auditory hallucinations Generalized catatonic rigidity Soon progressed to encephalopathy</td>
<td>NA</td>
<td>NA</td>
<td>Acute fulminant</td>
<td>NA</td>
<td>Delivered a normal baby Became akinetic mute in few months</td>
</tr>
<tr>
<td>Moodie 1980</td>
<td>South Africa</td>
<td>16/F</td>
<td>NA</td>
<td>NA</td>
<td>2 days</td>
<td>Schizophrenia</td>
<td>Paranoid behavior and auditory hallucinations</td>
<td>NA</td>
<td>NA</td>
<td>Acute fulminant</td>
<td>NA</td>
<td>Died 7 days later</td>
</tr>
<tr>
<td>Case</td>
<td>Age at Onset</td>
<td>Sex</td>
<td>Measles Age</td>
<td>Duration</td>
<td>Onset Symptoms</td>
<td>Features</td>
<td>Treatment</td>
<td>Complications</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>--------------</td>
<td>-----</td>
<td>-------------</td>
<td>----------</td>
<td>----------------</td>
<td>---------</td>
<td>-----------</td>
<td>---------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>3 years</td>
<td>NA</td>
<td>NA</td>
<td>6 months</td>
<td>Acute schizophrenia</td>
<td>Psychomotor retardation</td>
<td>Thioridazine</td>
<td>Died 2 years after</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>6 months</td>
<td>NA</td>
<td>NA</td>
<td>2 years</td>
<td>Childhood schizophrenia</td>
<td>Inappropriate laughter</td>
<td>Acute fulminant chlorpromazine</td>
<td>Died 1 year later</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>9F</td>
<td>NA</td>
<td>NA</td>
<td>9F</td>
<td>Childhood schizophrenia</td>
<td>Inappropriate laughter</td>
<td>Thioridazine</td>
<td>Died 2 years after</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Definitions
- **Acute schizophrenia**: Intense psychotic symptoms that arise suddenly and dissipate rapidly.
- **Childhood schizophrenia**: A type of schizophrenia that begins in childhood and can cause significant impairments in functioning.

### Symptoms
- **Psychomotor retardation**: Reduced physical or mental activity.
- **Inappropriate laughter**: An emotional response that does not match the situation.

### Treatment
- **Chlorpromazine**: A type of drug used to treat schizophrenia.
- **Thioridazine**: A medication used in the treatment of schizophrenia and other psychiatric conditions.

### Complications
- **Died**: Indicating death as a result of the condition or its treatment.

---

All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This version posted May 16, 2023. doi: medRxiv preprint
<table>
<thead>
<tr>
<th>Reference</th>
<th>Country</th>
<th>Age/Gender</th>
<th>Duration</th>
<th>Diagnosis</th>
<th>Symptoms/Tests</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salib 1988</td>
<td>United Kingdom</td>
<td>21/M</td>
<td>8 months</td>
<td>Schizophrenia-like state with bizarre dysmorphophobia</td>
<td>CT normal</td>
<td>Treated in psychiatry unit. Died 8 months later</td>
</tr>
<tr>
<td>Duncafl et al 1989</td>
<td>Australia</td>
<td>21/F</td>
<td>2 months</td>
<td>Schizophrenia</td>
<td>Delusions, Fearful and perplexed with echolalia, Lately withdrawn, agitated and had echolalia</td>
<td>Generalized grey matter atrophy, Diffuse demyelination, Inclusion bodies in neurons, Acute fulminant Fluphenazine. Psychotic symptoms improved, But had extrapyramidal side effects, Died within 6 months</td>
</tr>
<tr>
<td>Mattinson 1989</td>
<td>United Kingdom</td>
<td>44/F</td>
<td>Measles at 5 years</td>
<td>Functional psychiatric disorders</td>
<td>Poor recent memory, Emotional lability, Social disinhibition, Dysarthria and gait</td>
<td>Focal demyelination with gliosis, Inflammatory cell infiltration, Virus inclusion, Acute fulminant, Died 9 weeks later</td>
</tr>
<tr>
<td>Journal</td>
<td>Country</td>
<td>Gender</td>
<td>Age at Measles</td>
<td>Age at onset</td>
<td>Diagnosis</td>
<td>Symptoms</td>
</tr>
<tr>
<td>-----------------</td>
<td>------------</td>
<td>--------</td>
<td>----------------</td>
<td>-------------</td>
<td>------------------------------------</td>
<td>-------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Forrest and Stores 1996</td>
<td>United Kingdom</td>
<td>9/F</td>
<td>NA</td>
<td>4 months</td>
<td>Psychosis and possible sexual abuse</td>
<td>Nightmares seeing 'aliens' in a dream, Alleged attack by a bald man, Disorientated and uncooperative, Myoclonus and progressive encephalopathy</td>
</tr>
<tr>
<td>Jähnel 2003</td>
<td>Germany</td>
<td>19/M</td>
<td>NA</td>
<td>2 months</td>
<td>Schizophrenia</td>
<td>Auditory and visual hallucinations, Lack of interest, Decreased drive, Seizures and Myoclonus</td>
</tr>
<tr>
<td>Datta et al 2006</td>
<td>India</td>
<td>24/M</td>
<td>NA</td>
<td>5 months</td>
<td>Depression</td>
<td>Feeling sad, Loss of interest, Increased fatigue and lethargy, Multiple somatic complaints and insomnia</td>
</tr>
<tr>
<td>Study</td>
<td>Country</td>
<td>Age</td>
<td>Gender</td>
<td>Vaccination</td>
<td>Age at Onset of Measles</td>
<td>Duration Post Measles</td>
</tr>
<tr>
<td>-----------------------</td>
<td>---------</td>
<td>-----</td>
<td>--------</td>
<td>-------------</td>
<td>-------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Kayal et al 2006</td>
<td>India</td>
<td>13</td>
<td>M</td>
<td>No vaccination</td>
<td>2 months later</td>
<td>2 months</td>
</tr>
<tr>
<td>Theethira et al 2009</td>
<td>India</td>
<td>15</td>
<td>M</td>
<td>Not received</td>
<td>Several months</td>
<td>First episode schizophreniform disorder (International Classification of Diseases (ICD) F20.8)</td>
</tr>
<tr>
<td>Baran et al 2010</td>
<td>Turkey</td>
<td>31</td>
<td>M</td>
<td>NA</td>
<td>1 year</td>
<td>Schizophrenia Catatonia</td>
</tr>
<tr>
<td>Study</td>
<td>Country</td>
<td>Sex</td>
<td>Age</td>
<td>Duration</td>
<td>Diagnosis</td>
<td>Clinical Symptoms</td>
</tr>
<tr>
<td>------------------</td>
<td>---------</td>
<td>------</td>
<td>------</td>
<td>----------</td>
<td>-----------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Aggarwal et al 2011</td>
<td>India</td>
<td>13/M</td>
<td>NA</td>
<td>5 months</td>
<td>Catatonia</td>
<td>Withdrawn behavior and decreased interaction, mutism. Prolonged standing, clenching of teeth, violent behavior. Poor scholastic performance</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Akinetic mutism</td>
<td></td>
</tr>
<tr>
<td>Aggarwal et al 2011</td>
<td>India</td>
<td>14/M</td>
<td>NA</td>
<td>1 month</td>
<td>Mania</td>
<td>Behavioural changes. Became talkative, irritable and angry. Frequent bathing and reduced sleep. Increased psychomotor activity. Myoclonus and encephalopathy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Altunkaynak et al 2013</td>
<td>Turkey</td>
<td>19/F</td>
<td>NA</td>
<td>1 year</td>
<td>Atypical psychotic disorder</td>
<td>Behavioral changes. First episode schizophrenia and Admitted in psychiatry. Later, myoclonus and encephalopathy</td>
</tr>
<tr>
<td>Study</td>
<td>Country</td>
<td>Gender</td>
<td>Age</td>
<td>Duration</td>
<td>Diagnosis</td>
<td>Symptoms</td>
</tr>
<tr>
<td>------------------</td>
<td>----------</td>
<td>--------</td>
<td>-----</td>
<td>----------</td>
<td>-----------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Dayal and Balhara 2014</td>
<td>India</td>
<td>14/M</td>
<td>NA</td>
<td>6 months</td>
<td>Catatonia</td>
<td>Reduced interaction, Catatonic posture and clenching of teeth, Make poor eye contact and would resist attempts at moving him</td>
</tr>
<tr>
<td>Kartal et al 2014</td>
<td>Turkey</td>
<td>14/F</td>
<td>NA</td>
<td>3 months</td>
<td>Schizophrenia</td>
<td>Insomnia, Visual and auditory hallucinations, Behavioural changes and Mental decline, Agitation</td>
</tr>
<tr>
<td>Erdogan et al 2015</td>
<td>Turkey</td>
<td>20/M</td>
<td>NA</td>
<td>6 months</td>
<td>Mania</td>
<td>Manic episode, abnormal repetitive movements in his hands and legs and irritability, irritable and angry, worked for long hours and slept very little, He spent his money intemperately and bought himself new clothes every</td>
</tr>
<tr>
<td>Author(s)</td>
<td>Country</td>
<td>Age</td>
<td>Gender</td>
<td>Vaccination</td>
<td>Duration</td>
<td>Diagnosis</td>
</tr>
<tr>
<td>----------------</td>
<td>---------</td>
<td>-----</td>
<td>--------</td>
<td>-------------</td>
<td>----------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Manoj et al 2015</td>
<td>India</td>
<td>23/F</td>
<td>No</td>
<td>Present</td>
<td>1 year</td>
<td>Hypersexual syndrome</td>
</tr>
<tr>
<td>Parmar et al 2017</td>
<td>India</td>
<td>15/M</td>
<td>NA</td>
<td>NA</td>
<td>5 months</td>
<td>Schizophrenia catatonia</td>
</tr>
<tr>
<td>Tak et al 2017</td>
<td>Turkey</td>
<td>14/M</td>
<td>Fully vaccinated</td>
<td>measles infection at the age of 4 months</td>
<td>9 months</td>
<td>Nonspecific symptoms led to psychiatric consultation</td>
</tr>
</tbody>
</table>

The table above provides information on case studies of patients with various conditions and their behavioral abnormalities. The table includes the author(s), country, gender, vaccination status, duration, diagnosis, behavioral abnormalities, imaging findings, course, treatment, and outcome.
<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Gender</th>
<th>Age</th>
<th>Duration</th>
<th>Diagnosis</th>
<th>Symptoms</th>
<th>Imaging Findings</th>
<th>Treatment</th>
<th>Course</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ahmad et al 2018</td>
<td>India</td>
<td>26/M</td>
<td>NA</td>
<td>2 months</td>
<td>Acute and transient psychotic disorder</td>
<td>Withdrawn behavior, muttering to sell and inappropriate smiling, reduced self-care, impaired sleep and disorganized behavior, myoclonus and encephalopathy</td>
<td>T2/FLAIR hyperintensity foci in periventricular region mainly frontal-parietal region</td>
<td>T2/FLAIR</td>
<td>Olanzapine</td>
<td>Acute fulminant</td>
</tr>
<tr>
<td>Bhat et al 2018</td>
<td>India</td>
<td>8/M</td>
<td>NA</td>
<td>7 days</td>
<td>Childhood depression with antidepressant induced mania</td>
<td>Change in behaviour, excessive talking, overfamiliar behaviour, decreased sleep, spitting, excessive playing and hyperactivity</td>
<td>NA</td>
<td>Fluoxetine</td>
<td>Acute fulminant course</td>
<td>No improvement after 2 weeks</td>
</tr>
<tr>
<td>Reddy et al 2018</td>
<td>India</td>
<td>17/M</td>
<td>NA</td>
<td>1 year</td>
<td>Moderate depression</td>
<td>Poor scholastic performance, crying spells, and irritability, sudden drop of objects from hands, repeated falls, myoclonus</td>
<td>T2/FLAIR hyperintensity foci in periventricular region</td>
<td>Subacute</td>
<td>Psychotherapy and fluoxetine</td>
<td>NA</td>
</tr>
<tr>
<td>Author, Year</td>
<td>Country</td>
<td>Sex/Gender</td>
<td>Age</td>
<td>Duration</td>
<td>Diagnosis</td>
<td>Cognitive and Neuropsychological Features</td>
<td>Imaging Features</td>
<td>Treatment</td>
<td>Outcome</td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>---------</td>
<td>------------</td>
<td>-----</td>
<td>----------</td>
<td>-----------</td>
<td>------------------------------------------</td>
<td>-----------------</td>
<td>----------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>Gökoglu et al. 2019</td>
<td>Turkey</td>
<td>62/F</td>
<td>NA</td>
<td>3 years</td>
<td>Depression initially</td>
<td>Meaningless speech, Memory loss, Gait disorder</td>
<td>T2/FLAIR hyperintensity foci in periventricular region</td>
<td>NA</td>
<td>Chronic progressive</td>
<td>Amantadine</td>
</tr>
<tr>
<td>Arora et al. 2022</td>
<td>India</td>
<td>19/M</td>
<td>Incomplete</td>
<td>3 years</td>
<td>Schizophrenia</td>
<td>Apathy, personality change, Auditory and tactile hallucinations, Severe cognitive decline</td>
<td>NA</td>
<td>Chronic progressive</td>
<td>Aripiprazole</td>
<td>No further deterioration after 6 months</td>
</tr>
<tr>
<td>Sutar and Rai 2020</td>
<td>India</td>
<td>13/M</td>
<td>NA</td>
<td>8 months</td>
<td>Periodic catatonia</td>
<td>Acute abnormalities in sleep cycle, Episodes of slowness and excitement, Poor scholastic performance, Alternating episodes of slowness and excitement, Recurrent falls, Mutism, and psychomotor slowing, Intermittently, period of psychomotor agitation and</td>
<td>NA</td>
<td>Subacute</td>
<td>Lorazepam, Intrathecal interferon α2b</td>
<td>His oral intake and sleep improved.</td>
</tr>
<tr>
<td>Study</td>
<td>Country</td>
<td>Gender</td>
<td>Age</td>
<td>Duration</td>
<td>Diagnosis</td>
<td>Symptoms</td>
<td>Treatment</td>
<td>Outcome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>---------</td>
<td>--------</td>
<td>-----</td>
<td>----------</td>
<td>--------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>------------------------------------</td>
<td>-------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chakraborty et al 2021</td>
<td>India</td>
<td>15/M</td>
<td>NA</td>
<td>6 months</td>
<td>Catatonic schizophrenia</td>
<td>Smiling and muttering to self, Catatonia, Episodes of aggression, Attempts to run out of home, Poor self-care, Myoclonus, Epilepsy</td>
<td>Amisulpride and oral olanzapine, acute extrapyramidal side effects</td>
<td>Alive after more than 3 years of follow up.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaur et al 2021</td>
<td>India</td>
<td>17/F</td>
<td>NA</td>
<td>1 year</td>
<td>Schizophrenia</td>
<td>Behavioral changes, Social withdrawal, Irrelevant talk and laughter</td>
<td>Risperidone, No response</td>
<td>Became akinetic mute within few weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jain et al 2022</td>
<td>India</td>
<td>18/M</td>
<td>NA</td>
<td>4 months</td>
<td>Functional neurological disorder Later Catatonia</td>
<td>Behavioral changes, Unresponsive episodes, Soon became mute and had catatonic posture, Encephalopathy and</td>
<td>Levetiracetam, Lorazepam</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 3: Summary of epidemiological, clinical features, neuroimaging findings, histopathological features and outcome of patients of SSPE with psychiatric manifestations (n=32)

<table>
<thead>
<tr>
<th>Age (in years)</th>
<th>Mean</th>
<th>Median</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>19.4</td>
<td>17</td>
</tr>
</tbody>
</table>
|                      | Mode= 14  
|----------------------|------------------------------  
|                      | Range= 8-62                    
|                      | Interquartile Range= 7         
| Sex                  | Female= 11 (34.3%)                
|                      | Male= 21 (65.6%)                
| Measles vaccination  | Yes= 2 (6.2%)                   
|                      | No/NA= 30 (93.7%)               
| Childhood measles   | Yes= 10 (31.2%)                 
|                      | No or NA= 22 (68.8%)            
| Geographical areas of reported cases (total 30 reports) | India= 16 (53.3%)  
|                      | Europe, except Turkey = 5 (16.7%)  
|                      | Turkey= 6 (20%)                 
|                      | USA = 1 (3.3%)                  
|                      | Australia= 1 (3.3%)             
|                      | Africa= 1 (3.3%)                
| course of the disease | Acute fulminant= 19 (59.3%)  
|                      | Subacute= 7 (21.9%)             
|                      | Chronic =5 (16.6%)              
|                      | NA=1 (3.1%)                     
| Dominant psychiatric illness | Catatonia=3 (9.4%)  
|                      | Depression= 5 (16.6%)           
|                      | Functional neurological disorder/ Hysterical= 3 (9.4%)  
|                      | Hypersexuality=2 (6.3%)         
|                      | Mania= 2(6.3%)                  
|                      | Schizophrenia/ ill-defined psychotic disorders=16 (50%)  
|                      | Non-specific= 1(3.1%)           
| Neuroimaging         | NA= 16 (50%)                    
|                      | Normal= 6 (18.8%)               
|                      | T2/FLAIR periventricular hyperintensity= 8 (25%)  
|                      | Pontine hyperintensity= 1 (3.1%)  

All rights reserved. No reuse allowed without permission.
<table>
<thead>
<tr>
<th></th>
<th>Splenium of the corpus callosum hyperintensity =1 (3.1%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain biopsy</td>
<td>NA=29 (90.6%)</td>
</tr>
<tr>
<td></td>
<td>Done=3 (9.4%)</td>
</tr>
</tbody>
</table>

NA= not available; FLAIR= Fluid attenuated inversion recovery

### Legends

### Figure-1

PRISMA flow diagram of the study shows the process of article selection for systematic review.
Figure-2

Flow diagram depicts progression of course of disease in SSPE patients with psychiatric manifestations.
Identification of studies via databases and registers

Identification

Records identified from Databases = 453
PubMed = 143
Scopus = 56
Embase = 192
Google Scholar = 62

Records removed before screening:
Duplicate records removed = 148

Records screened = 305

Records excluded after review of title and abstract = 238

Reports sought for full text retrieval = 67
Reports not retrieved = 8

Reports assessed for eligibility = 59

Reports excluded = 29
Studies with no individual patient data = 2
Conference abstract only = 10
Book chapter/review article = 4
Psychiatric manifestations not reported = 6
Patients were not of SSPE = 5
Other irrelevant articles = 2

Reports of included in the review = 30
Total cases reported = 32
SSPE with psychiatric manifestations

- Acute fulminant course
  - Many patients were considered a malinger
  - Severe extrapyramidal manifestations
- Subacute course
  - Many patients inadvertently given antipsychotic drugs
- Chronic progressive course
  - Myoclonus Encephalopathy
  - Akinetic Mutism
  - Death